Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.79
Bid: 18.60
Ask: 18.98
Change: 0.00 (0.00%)
Spread: 0.38 (2.043%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.79
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Litigation Update

20 May 2021 07:00

RNS Number : 2166Z
Nanoco Group PLC
20 May 2021
 

20 May 2021

NANOCO GROUP PLC

("Nanoco", the "Company" or the "Group")

 

Litigation Update

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, announces an update on its litigation against Samsung for the alleged wilful infringement of the Group's IP.

 

On 17 February 2020, the Group announced that it had filed a patent infringement lawsuit against various Samsung entities in the United States District Court for the Eastern District of Texas (the 'Court').

 

As reported previously, Samsung had applied to the Patent Trial and Appeal Board (the 'PTAB') requesting the institution of inter partes reviews ('IPRs') of each of the five patents in the case. An IPR is a standard part of IP litigation and examines the validity of the patents themselves. It often runs in parallel with the judicial process.

 

The PTAB has now announced its decision to institute IPRs over the five patents. The evidential burden required to be passed in order to have an IPR granted is relatively low. For each patent, Samsung needed to show that there was a "reasonable likelihood that [they] would prevail with respect to at least 1 of the claims challenged in the petition.(1)" Samsung had submitted a number of grounds to challenge each claim and some of the patents have more than 20 asserted claims.

 

Where the PTAB finds that the evidential test has been met on at least one ground in one claim in each patent, then all of the claims in the patent in question are subject to the IPR process. This includes claims where the PTAB found that Samsung did not pass the evidential burden. At the end of the IPR process, the PTAB will rule on each individual claim as opposed to any of the patents as a whole.

 

A trial date for the jury hearing into the alleged wilful infringement of the Group's IP by Samsung has been set for October 2021, though Samsung may now seek (for a second time) to have this delayed until after the IPR process is complete. An IPR process can take 12 months to reach a conclusion and this can be followed by appeals.

 

Brian Tenner, Chief Executive Officer of Nanoco Group plc, said:

"We are not surprised that the PTAB has decided to implement the IPRs in the five patents and our plans included this eventuality. We note that many of Samsung's individual grounds of challenge were dismissed against a number of the claims asserted by Nanoco.

 

"Our confidence in the robustness and credibility of Nanoco's patents therefore remains unchanged with respect to the IPR process and the parallel judicial process, with any potential extension to the litigation timeframe underpinned by our third party litigation funding."

 

(1) 35 US Code 314 (a)

- Ends -

 

For further information, please contact:

Nanoco Group PLC: +44 (0) 161 603 7900

Brian Tenner, CEO

Liam Gray, Company Secretary

Caroline Watson, Investor Relations Manager

cwatson@nanocotechnologies.com

 

Peel Hunt: +44 (0) 20 7418 8900

Edward Knight

Nick Prowting

James Smith

 

MHP Communications: +44 (0) 203 128 8788

Reg Hoare

Giles Robinson

Pete Lambie

nanoco@mhpc.com

 

FORWARD LOOKING STATEMENTS

This announcement (including information incorporated by reference in this announcement), and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is their absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSFSEEUEFSESI
Date   Source Headline
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSDirectorate Changes
21st Jul 202011:25 amRNSHolding(s) in Company
20th Jul 202012:35 pmRNSHolding(s) in Company
16th Jul 20202:15 pmRNSDirector/PDMR Shareholding
16th Jul 20207:00 amRNSResult of Fund Raise
15th Jul 20205:20 pmRNSPrimaryBid.com Offer
15th Jul 20205:17 pmRNSTrading Update and Proposed Fundraising
14th Jul 20209:55 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSLitigation Funding Agreement
2nd Jul 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jul 20204:36 pmRNSPrice Monitoring Extension
30th Jun 202010:06 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSBlocklisting Six-Monthly Return
5th Jun 20204:41 pmRNSSecond Price Monitoring Extn
5th Jun 20204:35 pmRNSPrice Monitoring Extension
28th May 20207:00 amRNSQuantum Dot Material Supply Agreement
30th Apr 202012:00 pmRNSForm 8.5 (EPT/RI) - Nanoco Group PLC
30th Apr 20207:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.